Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report ...

The board of Gilead Sciences, Inc. (NASDAQ:GILD) has announced that it will be paying its dividend of $0.79 on the 28th of March, an increased payment from last year's comparable dividend.

Today, Kevin welcomes the co-chairs of MSU’s Health Sciences Council. The Health Sciences Council was convened under the guidance of the Office of the President to advise and support ...

All you need to do is bring your sense of wonder and a readiness to make a positive impact in the health and medical sciences. RIT is a Leader in Pass Rates for National Health Care and Medical ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin ...

Mace's team reported their findings February 18 in the Proceedings of the National Academy of Sciences. Our intuition told us that, because paper will have a defined saturation volume for a unit ...

Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $111.03. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, and downgraded Merck (NYSE:MRK), citing the cancer drugmaker’s ...